Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights from the Literature

  • Highlights from the Literature
    What We're Reading
    Cancer Immunol Res July 1 2017 5 (7) 515-515;

Priority Brief

  • Priority Brief
    Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
    Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li, Allegra A. Petti, Savas D. Soysal, Lijin Li, Mike D. McLellan, Jeremy Hoog, Tina Primeau, Nancy Myers, Tammi L. Vickery, Mark Sturmoski, Ian S. Hagemann, Chris A. Miller, Matthew J. Ellis, Elaine R. Mardis, Ted Hansen, Timothy P. Fleming, S. Peter Goedegebuure and William E. Gillanders
    Cancer Immunol Res July 1 2017 5 (7) 516-523; DOI:10.1158/2326-6066.CIR-16-0264

    Neoantigens are valuable for immunotherapy, but human breast cancers offer fewer than other cancers. With next-generation sequencing and computerized epitope-prediction, neoantigens in breast cancer were identified. The immune system recognized these neoantigens and protected mice from tumor challenge.

Research Articles

  • Research Articles
    A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
    Ti Wen, Zhenning Wang, Yi Li, Zhi Li, Xiaofang Che, Yibo Fan, Shuo Wang, Jinglei Qu, Xianghong Yang, Kezuo Hou, Wenyang Zhou, Ling Xu, Ce Li, Jin Wang, Jing Liu, Liqun Chen, Jingdong Zhang, Xiujuan Qu and Yunpeng Liu
    Cancer Immunol Res July 1 2017 5 (7) 524-534; DOI:10.1158/2326-6066.CIR-16-0381

    The American Joint Committee on Cancer (AJCC) staging system for gastric cancer is insufficiently prognostic. An immunoscore system based on PD-L1 expression on tumor or immune cells, PD-1 expression, and infiltration of CD8+ T cells was more prognostic and complements the AJCC system.

  • Research Articles
    Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
    Floris Dammeijer, Lysanne A. Lievense, Margaretha E. Kaijen-Lambers, Menno van Nimwegen, Koen Bezemer, Joost P. Hegmans, Thorbald van Hall, Rudi W. Hendriks and Joachim G. Aerts
    Cancer Immunol Res July 1 2017 5 (7) 535-546; DOI:10.1158/2326-6066.CIR-16-0309

    Mesothelioma has a poor prognosis and resists conventional therapies. Although tumor-associated macrophage depletion alone cannot restore antitumor immunity, its combination with dendritic cell–based therapy enhanced immune activation and survival in mesothelioma tumor models.

  • Research Articles
    All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages
    Qian Zhou, Miao Xian, Senfeng Xiang, Danyan Xiang, Xuejing Shao, Jincheng Wang, Ji Cao, Xiaochun Yang, Bo Yang, Meidan Ying and Qiaojun He
    Cancer Immunol Res July 1 2017 5 (7) 547-559; DOI:10.1158/2326-6066.CIR-16-0259

    Metastasis of osteosarcoma to lung depends on tumor-associated macrophages. All-trans retinoic acid (ATRA) inhibited this metastasis in mice. ATRA downregulated secretion of MMP12, a macrophage-secreted elastase. The results identify ATRA as a possible antimetastasis therapeutic.

  • Research Articles
    Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
    Jing Liao, Yan Luan, Zhenhua Ren, Xiaojuan Liu, Diyuan Xue, Hairong Xu, Zhichen Sun, Kaiting Yang, Hua Peng and Yang-Xin Fu
    Cancer Immunol Res July 1 2017 5 (7) 560-570; DOI:10.1158/2326-6066.CIR-16-0221

    Although mAbs to hCD20 are used therapeutically for B-cell lymphoma, some lymphomas are resistant. In mice, interferon-α (IFNα) abolished resistance. Treatment with an anti-CD20–IFNα fusion protein eradicated B-cell lymphoma by co-opting tumor cells to present antigen.

  • Research Articles
    Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
    Giedre Krenciute, Brooke L. Prinzing, Zhongzhen Yi, Meng-Fen Wu, Hao Liu, Gianpietro Dotti, Irina V. Balyasnikova and Stephen Gottschalk
    Cancer Immunol Res July 1 2017 5 (7) 571-581; DOI:10.1158/2326-6066.CIR-16-0376

    Glioblastoma responds imperfectly to immunotherapy. Transgenic expression of IL15 in T cells expressing chimeric antigen receptors improved their proliferative capacity, persistence, and cytokine production. The emergence of antigen-loss variants highlights the need to target multiple tumor antigens.

  • Research Articles
    Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
    Alexandra Frazao, Marina Colombo, Emmanuelle Fourmentraux-Neves, Meriem Messaoudene, Sylvie Rusakiewicz, Laurence Zitvogel, Eric Vivier, Frédéric Vély, Florence Faure, Brigitte Dréno, Houssem Benlalam, Fanny Bouquet, Ariel Savina, Eric Pasmant, Antoine Toubert, Marie-Françoise Avril and Anne Caignard
    Cancer Immunol Res July 1 2017 5 (7) 582-593; DOI:10.1158/2326-6066.CIR-16-0380

    Vemurafenib-treated melanomas of most patients whose tumors harbor BRAF mutations regress, but not durably. Vemurafenib, a Raf kinase-inhibitor, was found to alter expression of natural killer cell–recognized stress-induced ligands, which in turn affected natural killer cell cytotoxicity.

  • Research Articles
    Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
    Max Kates, Thomas Nirschl, Nikolai A. Sopko, Hotaka Matsui, Christina M. Kochel, Leonardo O. Reis, George J. Netto, Mohammad O. Hoque, Noah M. Hahn, David J. McConkey, Alex S. Baras, Charles G. Drake and Trinity J. Bivalacqua
    Cancer Immunol Res July 1 2017 5 (7) 594-603; DOI:10.1158/2326-6066.CIR-16-0267

    Intravesical bacillus Calmette–Guéerin (BCG) instillations are standard of care for early stage bladder cancer. BCG was found to recruit T cells to the bladder, but their phenotype was unchanged, implying that combining T cell–activating agents with BCG might improve clinical activity.

  • Research Articles
    Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
    Alessandra Fragale, Giulia Romagnoli, Valerio Licursi, Maria Buoncervello, Giorgia Del Vecchio, Caterina Giuliani, Stefania Parlato, Celeste Leone, Marta De Angelis, Irene Canini, Elena Toschi, Filippo Belardelli, Rodolfo Negri, Imerio Capone, Carlo Presutti and Lucia Gabriele
    Cancer Immunol Res July 1 2017 5 (7) 604-616; DOI:10.1158/2326-6066.CIR-17-0080

    A combination of two epidrugs plus IFN has antitumor effects in colorectal cancer. Epigenetic changes driven by IRF8 in both metastatic colorectal cancer cells and dendritic cells led to increased tumor cell death and increased activity of DCs.

Back to top
PreviousNext
Cancer Immunology Research: 5 (7)
July 2017
Volume 5, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • Highlights from the Literature
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement